Work

Clinical outcomes of chlormethine gel in mycosis fungoides affecting “sensitive” areas: A retrospective case series

Year: 2025

Type: article

Abstract: Dear Editors,Chlormethine (CL) gel is the first skin-directed therapy developed for the treatment of mycosis fungoides (MF). 1 It is recommended as a first-line treatment for adult patients with early-stage MF (IA-IIA) and, in combination with systemic therapies, for those in advanced stages, according to international guidelines.[2][3][4] Although clinical trials and realworld evidence support its efficacy, 5,6 application of CL gel to anatomically "sensitive" areas (e.g., face, anogenital, and intertriginous regions) remains challenging due to the risk of local adverse events (AEs), particularly irritant contact dermatitis (ICD).7 While some anecdotal evidence suggests that CL gel may be used in such sites, 8,9 there is a need for real-world data to elucidate its effectiveness and to detail management strategies for associated AEs.We conducted a retrospective case series at two Italian tertiary referral centers from January 2020 to April 2024.The study was approved by the Ethics Committee Milano Area 2 (Protocol No: 0007202).Eligible patients had a histologically confirmed diagnosis of MF with at least one "sensitive" area involved and were treated with CL gel.Assessments were performed at baseline and every 3 months, in accordance with standard clinical care and institutional protocols.The response was evaluated using a modified Composite Assess-

Source: JDDG Journal der Deutschen Dermatologischen Gesellschaft

DOI: 10.1111/ddg.15797